Complete response of metastatic microsatellite-stable <i>BRAF</i> V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade-Reference-Cited by-同舟云学术

Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade

Published:2024-06-28 Issue:1 Volume:13 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Ree Anne Hansen¹²^ORCID,Høye Eirik²³,Esbensen Ying²⁴,Beitnes Ann-Christin R.⁵,Negård Anne²⁶,Bernklev Linn²⁷,Tetlie Linn Kruse⁸,Fretland Åsmund A.⁹,Hamre Hanne M.¹,Kersten Christian¹¹⁰,Hofsli Eva¹¹¹²,Guren Marianne G.²¹³,Sorbye Halfdan¹⁴¹⁵,Nilsen Hilde L.²⁴¹⁶,Flatmark Kjersti²³¹⁷,Meltzer Sebastian¹

Affiliation:

1. Department of Oncology, Akershus University Hospital, Lørenskog, Norway

2. Institute of Clinical Medicine, University of Oslo, Oslo, Norway

3. Department of Tumor Biology, Oslo University Hospital, Oslo, Norway

4. Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway

5. Department of Pathology, Akershus University Hospital, Lørenskog, Norway

6. Department of Radiology, Akershus University Hospital, Lørenskog, Norway

7. Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway

8. Department of Oncology, Sørlandet Hospital, Kristiansand, Norway

9. The Intervention Centre and Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway

10. Department of Research, Sørlandet Hospital, Kristiansand, Norway

11. Department of Oncology, St. Olav’s Hospital, Trondheim, Norway

12. Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

13. Department of Oncology, Oslo University Hospital, Oslo, Norway

14. Department of Oncology, Haukeland University Hospital, Bergen, Norway

15. Department of Clinical Science, University of Bergen, Bergen, Norway

16. Department of Microbiology, Oslo University Hospital, Oslo, Norway

17. Department of Gastroenterological Surgery, Oslo University Hospital, Oslo, Norway

Funder

Bristol-Myers Squibb

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2024.2372886

Reference31 articles.

1. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

2. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

3. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency

4. The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors

5. The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review